Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
This study is being done to answer the following question:
The purpose of this study is to test the safety and tolerability of nivolumab alone and in combination with lirilumab to find out what effects, if any, it has on people.
CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER
1. Age ≥ 18 years at the time of consent
2. Confirmed urothelial cancer of the bladder
3. Eligible for cystectomy
4. Ineligible for cisplatin-based chemotherapy
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive a total of 4 weeks of neoadjuvant therapy followed by radical cystectomy within 6 weeks of the completion of neoadjuvant therapy.
You will be followed for 100 days after neoadjuvant treatment for safety and then you will be followed clinically and radiographically for at least 2 years post-cystectomy or when study-wide follow-up ends per standard of care.
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org